Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2; 2ФГБУН Научный центр неврологии РАН. 125367, Россия, Москва, Волоколамское ш., д. 80
Список исп. литературыСкрыть список 1. Porcelli S, Drago A, Fabbri C et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011; 36 (2): 87–113. 2. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 2012; 165 (2): 289–312. 3. Савельева М.И., Сычев Д.А., Казаков Р.Е. и др. Значение генетического полиморфизма изоферментов цитохрома Р450 для персонализированного выбора и режимов дозирования антидепрессантов и антипсихотиков. Клин. медицина. 2008; 86 (11): 22–8. / Savel'eva M.I., Sychev D.A., Kazakov R.E. i dr. Znachenie geneticheskogo polimorfizma izofermentov tsitokhroma R450 dlia personalizirovannogo vybora i rezhimov dozirovaniia antidepressantov i antipsikhotikov. Klin. meditsina. 2008; 86 (11): 22–8. [in Russian] 4. Кукес В.Г., Иванец Н.Н., Сычев Д.А. и др. Влияние генетического полиморфизма CYP2D6 и MDR1 на эффективность и безопасность терапии антидепрессантами у пациентов с депрессивными расстройствами в условиях психиатрического стационара. Психиатрия и психофармакотерапия. 2013; 15 (5): 11–5. / Kukes V.G., Ivanets N.N., Sychev D.A. i dr. Vliianie geneticheskogo polimorfizma CYP2D6 i MDR1 na effektivnost' i bezopasnost' terapii antidepressantami u patsientov s depressivnymi rasstroistvami v usloviiakh psikhiatricheskogo statsionara. Psikhiatriia i psikhofarmakoterapiia. 2013; 15 (5): 11–5. [in Russian] 5. Ташенова А.И., Исмагилов Т.Г., Савельева М.И., Кукес В.Г. Влияние полиморфизма гена MDR1, кодирующего Р-гликопротеин, на развитие неблагоприятных побочных реакций при применении антидепрессантов в условиях стационара психиатрического профиля. Биомедицина. 2010; 1 (4): 46–50. / Tashenova A.I., Ismagilov T.G., Savel'eva M.I., Kukes V.G. Vliianie polimorfizma gena MDR1, kodiruiushchego R-glikoprotein, na razvitie neblagopriiatnykh pobochnykh reaktsii pri primenenii antidepressantov v usloviiakh statsionara psikhiatricheskogo profilia. Biomeditsina. 2010; 1 (4): 46–50. [in Russian] 6. Serretti A, Kato M, De Ronchi D et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247–57. 7. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22 (4): 239–58. 8. Smits K, Smits L, Peeters F et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2007; 22 (3): 137–43. 9. Perlis RH, Mischoulon D, Smoller JW et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003; 54 (9): 879–83. 10. Ferreira Ade A, Neves FS, da Rocha FF et al. The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J Affect Disord 2009; 112 (1–3): 267–72. 11. Jr Murphy GM, Hollander SB, Rodrigues HE et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61 (11): 1163–9. 12. Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot study. Pharmacogenomics 2006; 7 (2): 159–66. 13. Lanctot KL, Rapoport MJ, Chan F et al. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Inj 2010; 24 (7–8): 959–69. 14. Hodgson K, Uher R, Crawford AA et al. Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Psychopharmacol 2014; 28 (2): 142–50. 15. Ng C, Sarris J, Singh A et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol 2013; 28 (5): 516–22. 16. Smits KM, Smits LJ, Peeters FP et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008; 11: 184–90. 17. Kirchheiner J, Nickchen K, Sasse J et al. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics 2007; 7 (1): 48–55. 18. Lavretsky H, Siddarth P, Kumar A, Reynolds CF 3rd. The effects of dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study. Int J Geriatr 2008; 23 (1): 55–9. 19. Kunugi H, Hattori M, Kato T et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997; 2: 457–62. 20. Kang AM, Palmatier MA, Kidd KK. Global Variation of a 40-bp VNTR in the 3’-Untranslated Region of the Dopamine Transporter Gene (SLC6A3). Biol Psychiatry 1999; 46: 151–60.